Behcet Disease - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Behcet Disease - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Behcet Disease - Pipeline Review, H1 2016', provides an overview of the Behcet Disease pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Behcet Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Behcet Disease
- The report reviews pipeline therapeutics for Behcet Disease by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Behcet Disease therapeutics and enlists all their major and minor projects
- The report assesses Behcet Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Behcet Disease


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Behcet Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Behcet Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Behcet Disease Overview 6
Therapeutics Development 7
Pipeline Products for Behcet Disease - Overview 7
Behcet Disease - Therapeutics under Development by Companies 8
Behcet Disease - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Behcet Disease - Products under Development by Companies 12
Behcet Disease - Companies Involved in Therapeutics Development 13
AbbVie Inc. 13
Celgene Corporation 14
Delenex Therapeutics AG 15
Genor BioPharma Co., Ltd. 16
HanAll Biopharma Co., Ltd. 17
Mabion SA 18
Mycenax Biotech Inc. 19
R-Pharm 20
Behcet Disease - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
adalimumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
adalimumab biosimilar - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
adalimumab biosimilar - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
apremilast - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
DLX-105 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HL-143 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
infliximab biosimilar - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RPH-104 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Behcet Disease - Recent Pipeline Updates 45
Behcet Disease - Dormant Projects 62
Behcet Disease - Discontinued Products 63
Behcet Disease - Product Development Milestones 64
Featured News & Press Releases 64
Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir 64
Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet 65
Apr 15, 2015: Phase II Data for Apremilast in Behcet's Disease Published in The New England Journal of Medicine 65
Apr 14, 2015: Delenex Announces New Clinical Data 67
Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behcet's Disease At EULAR 67
May 24, 2013: AbbVie And Eisai Receive Indication Approval For Treatment Of Intestinal Behcet's Disease For Humira Pre-filled Syringe In Japan 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for Behcet Disease, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Behcet Disease - Pipeline by AbbVie Inc., H1 2016 13
Behcet Disease - Pipeline by Celgene Corporation, H1 2016 14
Behcet Disease - Pipeline by Delenex Therapeutics AG, H1 2016 15
Behcet Disease - Pipeline by Genor BioPharma Co., Ltd., H1 2016 16
Behcet Disease - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 17
Behcet Disease - Pipeline by Mabion SA, H1 2016 18
Behcet Disease - Pipeline by Mycenax Biotech Inc., H1 2016 19
Behcet Disease - Pipeline by R-Pharm, H1 2016 20
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Behcet Disease Therapeutics - Recent Pipeline Updates, H1 2016 45
Behcet Disease - Dormant Projects, H1 2016 62
Behcet Disease - Discontinued Products, H1 2016 63